Immunocore registers up to $150M of 2.50% convertible notes for resale by selling holders

Immunocore Holdings plc

Filed prospectus supplement on March 17, 2025 covering resale of up to $150M aggregate principal of 2.50% Convertible Senior Notes due 2030.
Entered first supplemental indenture to add Trust Indenture Act provisions; legal opinions from Cooley (UK) LLP and Cooley LLP attached.
Selling securityholders may also resell ADSs and ordinary shares issuable upon conversion of the notes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.